BioNexus Gene Lab 10-K: Revenue $7.42M, EPS $(1.61)
I'm LongbridgeAI, I can summarize articles.BioNexus Gene Lab reported a fiscal-year revenue of $7.42 million, a 21.9% decline year-over-year, with a net loss per share of $(1.61). The company faced an 88% increase in operating losses, totaling $(2.965) million. Gross profit was $1.085 million, improving gross margin to 14.7%. Key highlights include a shift in revenue channels, expansion into diagnostics, and a new Ethereum-focused treasury strategy. The company is addressing governance issues at Chemrex and has partnered with ML Tech for digital asset integration.
BioNexus Gene Lab reported fiscal-year revenue of $7.42 million and a net loss per share of $(1.607), reflecting a 21.9% decline in revenue driven by lower Chemrex volume and foreign exchange translation and a wider operating loss. The company recorded a net loss attributable to common shareholders of $(2.985) million on operating losses that increased 88% year-over-year. Gross profit was $1.085 million with a modest improvement in gross margin to 14.7%.
Financial Highlights
- Revenue: $7.42 million, decreased 21.9% year-over-year due to lower Chemrex volume and FX translation.
- Gross Profit: $1.085 million (gross margin 14.7% in 2025 vs 13.7% in 2024).
- Loss from Operations: $(2.965) million; operating loss increased 88% year-over-year.
- Net Loss Attributable to Common Shareholders: $(2.985) million, versus $(1.598) million in the prior year.
- Earnings per Share — Basic and Diluted: $(1.607); weighted average shares outstanding 1,856,680.
Business Highlights
- Revenue Trend: Revenue declined roughly 22% year-over-year, primarily from reduced Chemrex sales volume following management changes.
- Channel & Mix Shift: Chemrex remained the dominant channel (~99.7% of revenue); an improved product mix contributed to a slight uptick in gross margin.
- Diagnostics and Strategic Moves: Expanded into diagnostics via a Fidelion license and announced plans to advance VitaGuard™ MRD in Southeast Asia through a contemplated 15% equity stake.
- Operational Remediation: An audit identified governance and control lapses at Chemrex; remediation actions include updated approval workflows and a claims assessment process.
- Digital Treasury & Partnerships: Announced an Ethereum-focused treasury strategy and a partnership with ML Tech to integrate digital asset and AI capabilities into operations.
Original SEC Filing: BioNexus Gene Lab Corp [ BGLC ] - 10-K - Apr. 14, 2026